WallStreetZenWallStreetZen

NASDAQ: IMDX
Insight Molecular Diagnostics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IMDX

Based on 1 analyst offering 12 month price targets for Insight Molecular Diagnostics Inc

Min Forecast
$12.00+109.79%
Avg Forecast
$12.00+109.79%
Max Forecast
$12.00+109.79%

Should I buy or sell IMDX stock?

Based on 1 analyst offering ratings for Insight Molecular Diagnostics Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although IMDX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates IMDX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their IMDX stock forecasts and price targets.

IMDX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-02-17

1 of 1

Forecast return on equity

Is IMDX forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is IMDX forecast to generate an efficient return on assets?

Company
N/A
Industry
12.63%

IMDX earnings per share forecast

What is IMDX's earnings per share in the next 2 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$0.87
Avg 2 year Forecast
-$0.90

IMDX revenue forecast

What is IMDX's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$2.2M+12.37%
Avg 2 year Forecast
$7.9M+304.31%
Avg 3 year Forecast
$29.9M+1,433.4%
IMDX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

IMDX revenue growth forecast

How is IMDX forecast to perform vs Diagnostics & Research companies and vs the US market?

Company
153.67%
Industry
8.73%
Market
16.49%
IMDX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
IMDX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

IMDX vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
IMDX$5.72$12.00+109.79%Strong Buy
BDSX$14.95$22.00+47.16%Strong Buy
XGN$4.20$9.00+114.29%Strong Buy
BNR$9.07N/AN/A
STIM$1.28$3.00+134.38%Strong Buy
View Top Diagnostic & Research Stocks

Insight Molecular Diagnostics Stock Forecast FAQ

Is Insight Molecular Diagnostics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: IMDX) stock is to Strong Buy IMDX stock.

Out of 1 analyst, 1 (100%) are recommending IMDX as a Strong Buy, 0 (0%) are recommending IMDX as a Buy, 0 (0%) are recommending IMDX as a Hold, 0 (0%) are recommending IMDX as a Sell, and 0 (0%) are recommending IMDX as a Strong Sell.

If you're new to stock investing, here's how to buy Insight Molecular Diagnostics stock.

What is IMDX's earnings growth forecast for 2026-2027?

(NASDAQ: IMDX) Insight Molecular Diagnostics's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 24.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 69.01%.

Insight Molecular Diagnostics's earnings in 2026 is -$47,841,000.On average, 6 Wall Street analysts forecast IMDX's earnings for 2026 to be -$28,160,255, with the lowest IMDX earnings forecast at -$29,112,815, and the highest IMDX earnings forecast at -$26,106,600.

In 2027, IMDX is forecast to generate -$28,973,967 in earnings, with the lowest earnings forecast at -$32,244,961 and the highest earnings forecast at -$26,784,694.

What is IMDX's revenue growth forecast for 2026-2028?

(NASDAQ: IMDX) Insight Molecular Diagnostics's forecast annual revenue growth rate of 153.67% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.73%, and it is also forecast to beat the US market's average forecast revenue growth rate of 16.49%.

Insight Molecular Diagnostics's revenue in 2026 is $1,949,000.On average, 6 Wall Street analysts forecast IMDX's revenue for 2026 to be $70,715,466, with the lowest IMDX revenue forecast at $31,296,276, and the highest IMDX revenue forecast at $101,714,026. On average, 6 Wall Street analysts forecast IMDX's revenue for 2027 to be $254,446,516, with the lowest IMDX revenue forecast at $41,137,673, and the highest IMDX revenue forecast at $403,465,637.

In 2028, IMDX is forecast to generate $965,023,931 in revenue, with the lowest revenue forecast at $927,179,855 and the highest revenue forecast at $993,406,988.

What is IMDX's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: IMDX) forecast ROA is N/A, which is lower than the forecast US Diagnostics & Research industry average of 12.63%.

What is IMDX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year IMDX price target, the average IMDX price target is $12.00, with the highest IMDX stock price forecast at $12.00 and the lowest IMDX stock price forecast at $12.00.

The Wall Street analyst predicted that Insight Molecular Diagnostics's share price could reach $12.00 by Feb 17, 2027. The average Insight Molecular Diagnostics stock price prediction forecasts a potential upside of 109.79% from the current IMDX share price of $5.72.

What is IMDX's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: IMDX) Insight Molecular Diagnostics's current Earnings Per Share (EPS) is -$1.50. On average, analysts forecast that IMDX's EPS will be -$0.87 for 2026, with the lowest EPS forecast at -$0.90, and the highest EPS forecast at -$0.81. In 2027, IMDX's EPS is forecast to hit -$0.90 (min: -$1.00, max: -$0.83).

What is IMDX's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: IMDX) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.